Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene Del Molino Del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, Thomas S Hayday, Carl Graham, Jeffrey Seow, Sultan Abdul-Jawad, Shraddha Kamdar, Elizabeth Harvey-Jones, Rosalind Graham, Jack Cooper, Muhammad Khan, Jennifer Vidler, Helen Kakkassery, Shubhankar Sinha, Richard DavisLiane Dupont, Isaac Francos Quijorna, Charlotte O'Brien-Gore, Puay Ling Lee, Josephine Eum, Maria Conde Poole, Magdalene Joseph, Daniel Davies, Yin Wu, Angela Swampillai, Bernard V North, Ana Montes, Mark Harries, Anne Rigg, James Spicer, Michael H Malim, Paul Fields, Piers Patten, Francesca Di Rosa, Sophie Papa, Timothy Tree, Katie J Doores, Adrian C Hayday, Sheeba Irshad

Research output: Contribution to journalArticlepeer-review

459 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology